Description de l'entreprise
Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. Moderna’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune and inflammatory diseases, independently and with strategic collaborators.
Conseil d'administration & Conseil de surveillance
| PDG |
| Stéphane Bancel |
| Conseil d'administration |
| Jamey Mock, Stephen Hoge, M.D., Jerh Collins, Ph.D., Kate Cronin, Tracey Franklin, Shannon Thyme Klinger, Brad Miller |
| Conseil de surveillance |
| Dr. Noubar Afeyan, Stéphane Bancel, Sandra Horning, M.D., Abbas Hussain, Elizabeth Nabel, M.D., François Nader, M.D., David Rubenstein, Paul Sagan, Elizabeth Tallett, Henri A. Termeer |
Données de l'entreprise
| Nom: |
Moderna Inc. |
| Adresse: |
200 Technology Square,Cambridge, Massachusetts 02139, USA |
| Téléphone: |
+1-617-714-6500 |
| Fax: |
+1-617-583-1998 |
| Courriel: |
info@modernatx.com
|
| Internet: |
https://www.modernatx.com/ |
| Industrie: |
Biotechnology |
| Secteur: |
Biotechnology |
| Sous-secteur: |
Biotechnology |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
- |
| IPO date: |
07/12/2018 |
Relations avec les investisseurs
| Nom: |
- |
| Téléphone IR: |
- |
| IR-Fax: |
- |
| E-mail IR: |
IR@modernatx.com
|
